Hypertension remains a silent killer, significantly elevating the risk of cardiovascular events and other health complications. While the importance of blood pressure control is well established, emerging research suggests that blood pressure variability (BPV) may be a crucial, yet often overlooked, factor in assessing cardiovascular risk and target organ damage. Join us as our Expert Panel will unravel the intricate connections between blood pressure variability and target organ damage, covering: Cardiac,Neurological, Hepatic, Vascular impacts and Renal implications.

Beyond Standard Measures: Blood Pressure Variability and Its Implications for Target Organ Damage

In this dynamic panel discussion we explore antiplatelet strategies for CAD in high-bleeding risk (HBR) patients. They also revisit aspirin's role in primary CVD prevention. Gain insights into evolving antiplatelet therapies, balancing benefits and bleeding risks, and discover evidence-based approaches for optimizing CAD patient outcomes. Join us live for this insightful discussion. Educational Initiative supported by AstraZeneca.

Antiplatelet regimes in CAD in HBR subset, and revisiting Aspirin in Primary CVD prevention

Head of Department - Cardiology, AMRI Hospitals, Kolkata

This panel discussion brings together key perspectives on the interplay between heart, metabolic, and renal health, highlighting how SGLT2 inhibitor and DPP-4 inhibitor combinations are reshaping outcomes in patients with diabetes and associated co-morbidities. The session focuses on real-world evidence, patient selection, cardio-renal protection, and practical treatment strategies to achieve comprehensive cardio-renal-metabolic benefits in routine clinical practice.

Dr. PK Hazra

5

2.2k

59.9k

4.8

Upcoming Sessions

Sessions Taken

1.4k

4.7

765

5